Halozyme Therapeutics Inc (HALO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $11.43B
Last updated: Nov 17, 2026 at 11:06 AM ET
Halozyme Therapeutics Inc (HALO) P/E Ratio & Valuation History
Halozyme Therapeutics (HALO) trades at 17.8x trailing earnings and 6.1x sales. Its P/E of 17.8x is above its 5-year median of 15.8x. Its forward P/E is 10.6x. The median P/E across 7 similar companies is 39.6x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 67.9% higher over the next year. Its free cash flow yield is 8.1%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 17.8x |
| Forward P/E | 10.6x |
| Price to sales | 6.1x |
| EV/EBITDA | 16.1x |
| Price to FCF | 12.4x |
| EV/FCF | 14.9x |
| PEG | N/A |
| FCF yield | 8.1% |
Historical Medians
Against its 10-year medians, its P/S is 39.0% below 10.0x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/E | 17.8x | 15.8x | N/A |
| P/S | 6.1x | 7.2x | 10.0x |
| P/B | N/A | 26.9x | 27.2x |
Valuation History
Over the 7 of the 10 year ends shown that have a P/E, its P/E ranged from 11.3x in 2024 to 53.3x in 2017.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $67.30 | 16.3x | 5.8x | 162.2x |
| 2024 | $47.81 | 11.3x | 6.0x | 17.0x |
| 2023 | $36.96 | 13.3x | 5.9x | 57.8x |
| 2022 | $56.90 | 25.6x | 11.9x | 46.4x |
| 2021 | $40.21 | 20.1x | 12.9x | 29.5x |
| 2020 | $42.71 | 47.5x | 22.4x | 41.0x |
| 2019 | $17.73 | N/A | 13.0x | 27.3x |
| 2018 | $14.63 | N/A | 13.8x | 8.5x |
| 2017 | $20.26 | 53.3x | 9.1x | 14.2x |
| 2016 | $9.88 | N/A | 8.6x | N/A |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About HALO
What is HALO's forward P/E ratio?
Halozyme Therapeutics has a forward P/E ratio of 10.6x.
Is HALO stock overvalued?
GNG's valuation label for HALO is Undervalued. Its P/E of 17.8x compares with a median of 39.6x across 7 similar companies.
What is HALO's price to sales ratio?
Halozyme Therapeutics has a price to sales ratio of 6.1x.
What is Halozyme Therapeutics's average P/E ratio over 5 years?
Halozyme Therapeutics's median P/E over the last 5 years is 15.8x, from 60 month-end values through Oct 2026.
HALO pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors